Logo
x

Search

Subscribe Now

Abbvie

AbbVie’s Elahere (Mirvetuximab Soravtansine) Receives the EC’s Approval to Treat Platinum-Resistant Ovarian Cancer

AbbVie’s Elahere (Mirvetuximab Soravtansine) Receives the EC’s Approval to Treat Platinum-Resistant Ovarian Cancer

  • November 18, 2024
AbbVie Reports the P-II (EMPOWER) Studies Data of Emraclidine for Treating Schizophrenia

AbbVie Reports the P-II (EMPOWER) Studies Data of Emraclidine for Treating Schizophrenia

  • November 12, 2024
AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology

AbbVie Join Forces with EvolveImmune Therapeutics for Developing Next-Generation Biotherapeutics in Oncology

  • November 4, 2024
AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions

AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions

  • October 25, 2024
AbbVie Reports the US FDA’s Approval of Botox Cosmetic (OnabotulinumtoxinA) for Moderate to Severe Vertical Bands Connecting the Jaw and Neck

AbbVie Reports the US FDA’s Approval of Botox Cosmetic (OnabotulinumtoxinA) for Moderate to Severe Vertical Bands Connecting the J...

  • October 21, 2024
AbbVie Reports the US FDA’s Approval of Vyalev (Foscarbidopa and Foslevodopa) for Treating Advanced Parkinson's Disease

AbbVie Reports the US FDA’s Approval of Vyalev (Foscarbidopa and Foslevodopa) for Treating Advanced Parkinson's Disease

  • October 18, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.